Journal
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
Volume 96, Issue 3, Pages 206-211Publisher
BLACKWELL MUNKSGAARD
DOI: 10.1111/j.1742-7843.2005.pto960310.x
Keywords
-
Categories
Ask authors/readers for more resources
For many oncological agents, myelosuppression is the dose-limiting toxicity and the quantitative characterisation of the relationship between drug dose, plasma concentration and haematological toxicity is of importance in the drug development. Mechanism-based population pharmacokinetic-pharmacodynamic models have been developed for this purpose and the applications of these in candidate selection, first-in-man studies, prodrug and formulation development, dose finding, schedule optimisation, assessing influence of modifying agents, drug combination studies, subgroup identification and feedback individualisation are reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available